drugset / Trial / NCT03597139

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

NCT03597139

Phase 2 Completed 100 enrolled Aurinia Pharmaceuticals Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).

Timeline

Start
2018-08-13
Primary completion
2018-11-09
Completion
2018-12-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 0.05 % Other
Subject Voclosporin Other / unclassified 0.2 % Other

Indications